



Section: [11. Blood products of human origin and plasma substitutes](#) > [11.2. Plasma-derived medicines](#) > [11.2.1. Human immunoglobulins](#)

EMLc

ATC codes: [J06BB05](#)

Indication	Rabies <a href="#">ICD11 code: 1C82</a>
Medicine type	Biological agent
List type	Core All human plasma-derived medicines should comply with the WHO requirements
Formulations	Parenteral > General injections > IM: 150 IU per mL in vial Parenteral > Locoregional injections > Other: 150 IU per mL in vial
EML status history	First added in 1991 ( <a href="#">TRS 825</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2013 ( <a href="#">TRS 985</a> ) Changed in 2015 ( <a href="#">TRS 994</a> )
Sex	All
Age	Also recommended for children
Therapeutic equivalence	The recommendation is for this specific medicine
Patent information	Read more <a href="#">about patents</a> .
Wikipedia	<a href="#">Anti-rabies immunoglobulin</a>
DrugBank	<a href="#">Anti-rabies immunoglobulin (Human rabies virus immune globulin)</a>

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended that immunoglobulins of human origin currently listed in Section 19.2 Sera and immunoglobulins, should be transferred to Section 11.2.1 Human immunoglobulins.

